Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005333 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2019.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osimertinib-associated erythema dyschromicum perstans-like eruption: A case series.
JAAD Case Rep
May 2023
Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
Rare ashy dermatosis-like hyperpigmentation associated with osimertinib.
Thorac Cancer
May 2022
First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the most reliable EGFR-TKI and is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer. Pigmentary changes caused by EGFR-TKIs are unusual, and to the best of my knowledge, hyperpigmentation with osimertinib has rarely been reported as a skin-related adverse event. Here, I report a case of osimertinib-associated ashy dermatosis-like hyperpigmentation on imaging.
View Article and Find Full Text PDFOsimertinib-associated ashy dermatosis-like hyperpigmentation.
JAAD Case Rep
February 2020
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!